Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(S)-3,5-DHPG (HB0045)
Description:Selective group I mGlu receptor agonist. Induces LTD.
Purity:>99%
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq DREADD receptor.
Kainic acid (HB0355)
Description:Prototypic, selective kainate receptor agonist. Potent excitant and neurotoxin.
Purity:>98%
Pam3CSK4 (HB3428)
Description:TLR1/TLR2 agonist and potent NF-κB activator. Induces cytokine production.